All News

Agency leaders go slow in weighing changes to DTC ads and off-label marketing. Jill Wechsler reports.

Our annual look at the drug industry's pipeline-the progress and the setbacks-puts my thoughts on those people driving new science behind the scenes in pharmaceutical research.

A deep dive into the outlook and implications from the UK’s recently unveiled life sciences blueprint for a post-Brexit world.

Outlining the common data transactions between life sciences companies and the HIPAA-regulated stakeholders they deal with daily-and steps pharma can take to secure and protect its own data.

Navigating Data Privacy and Security Considerations in the Life Sciences Industry

Brenda Gleason discusses the current health policy landscape and how future pharmacists can be healthcare leaders during a lecture at University of North Carolina Eshelman School of Pharmacy.

Click the title above to open the Pharmaceutical Executive October 2017 issue in an interactive PDF format.